174 related articles for article (PubMed ID: 33575471)
1. Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer.
Yang D; Chen T; Zhan M; Xu S; Yin X; Liu Q; Chen W; Zhang Y; Liu D; Yan J; Huang Q; Wang J
Mol Ther Oncolytics; 2021 Mar; 20():59-70. PubMed ID: 33575471
[TBL] [Abstract][Full Text] [Related]
2. HKI-272 contributes to gemcitabine-mediated anti-proliferative and anti-metastatic effects through EGFR suppression in gallbladder cancer.
Yang X; Chen T; Hu J; Wang J; Yang D
Mol Ther Oncolytics; 2022 Dec; 27():126-140. PubMed ID: 36321135
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.
Cao Y; Liu X; Lu W; Chen Y; Wu X; Li M; Wang XA; Zhang F; Jiang L; Zhang Y; Hu Y; Xiang S; Shu Y; Bao R; Li H; Wu W; Weng H; Yen Y; Liu Y
Cancer Lett; 2015 May; 360(2):141-50. PubMed ID: 25657110
[TBL] [Abstract][Full Text] [Related]
4. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
Mohri D; Ijichi H; Miyabayashi K; Takahashi R; Kudo Y; Sasaki T; Asaoka Y; Tanaka Y; Ikenoue T; Tateishi K; Tada M; Isayama H; Koike K
J Gastroenterol; 2016 Jul; 51(7):711-21. PubMed ID: 26614007
[TBL] [Abstract][Full Text] [Related]
5. FOXK1 Promotes Proliferation and Metastasis of Gallbladder Cancer by Activating AKT/mTOR Signaling Pathway.
Wencong M; Jinghan W; Yong Y; Jianyang A; Bin L; Qingbao C; Chen L; Xiaoqing J
Front Oncol; 2020; 10():545. PubMed ID: 32363163
[TBL] [Abstract][Full Text] [Related]
6. Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
Cao Y; Liang H; Zhang F; Luan Z; Zhao S; Wang XA; Liu S; Bao R; Shu Y; Ma Q; Zhu J; Liu Y
J Exp Clin Cancer Res; 2016 Apr; 35():68. PubMed ID: 27084680
[TBL] [Abstract][Full Text] [Related]
7. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
Yang P; Javle M; Pang F; Zhao W; Abdel-Wahab R; Chen X; Meric-Bernstam F; Chen H; Borad MJ; Liu Y; Zou C; Mu S; Xing Y; Wang K; Peng C; Che X
Hepatobiliary Surg Nutr; 2019 Dec; 8(6):604-614. PubMed ID: 31929987
[TBL] [Abstract][Full Text] [Related]
8. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.
Shen H; He M; Lin R; Zhan M; Xu S; Huang X; Xu C; Chen W; Yao Y; Mohan M; Wang J
J Exp Clin Cancer Res; 2019 Jun; 38(1):247. PubMed ID: 31182136
[TBL] [Abstract][Full Text] [Related]
9. ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation.
Zhang X; Kong Z; Xu X; Yun X; Chao J; Ding D; Li T; Gao Y; Guan N; Zhu C; Qin X
J Cancer; 2021; 12(7):1926-1935. PubMed ID: 33753990
[TBL] [Abstract][Full Text] [Related]
10. A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth.
Zhang Y; Liu S; Wang L; Wu Y; Hao J; Wang Z; Lu W; Wang XA; Zhang F; Cao Y; Liang H; Li H; Ye Y; Ma Q; Zhao S; Shu Y; Bao R; Jiang L; Hu Y; Zhou J; Chen L; Liu Y
Cancer Lett; 2016 May; 375(1):179-189. PubMed ID: 26949052
[TBL] [Abstract][Full Text] [Related]
11. STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma.
Hu YP; Wu ZB; Jiang L; Jin YP; Li HF; Zhang YJ; Ma Q; Ye YY; Wang Z; Liu YC; Chen HZ; Liu YB
Int J Biochem Cell Biol; 2018 Apr; 97():16-27. PubMed ID: 29413947
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma.
Leal P; García P; Sandoval A; Letelier P; Brebi P; Ili C; Álvarez H; Tapia O; Roa JC
Arch Pathol Lab Med; 2013 Apr; 137(4):552-7. PubMed ID: 23544944
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of gallbladder cancer: An update.
Mishra SK; Kumari N; Krishnani N
Mutat Res; 2019 Nov; 816-818():111674. PubMed ID: 31330366
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review.
Montalvo-Jave EE; Rahnemai-Azar AA; Papaconstantinou D; Deloiza ME; Tsilimigras DI; Moris D; Mendoza-Barrera GE; Weber SM; Pawlik TM
Surg Oncol; 2019 Dec; 31():83-89. PubMed ID: 31541911
[TBL] [Abstract][Full Text] [Related]
15. SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling.
Qin Y; Meng L; Fu Y; Quan Z; Ma M; Weng M; Zhang Z; Gao C; Shi X; Han K
Oncotarget; 2017 Mar; 8(12):19980-19996. PubMed ID: 28212545
[TBL] [Abstract][Full Text] [Related]
16. Dickkopf Homolog 3
Gondkar K; Patel K; Patil Okaly GV; Nair B; Pandey A; Gowda H; Kumar P
Front Oncol; 2019; 9():1121. PubMed ID: 31737564
[TBL] [Abstract][Full Text] [Related]
17. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Endothelin-1 pathway to reduce invasion and chemoresistance in gallbladder cancer cells.
Rodas F; Vidal-Vidal JA; Herrera D; Brown-Brown DA; Vera D; Veliz J; Püschel P; Erices JI; Sánchez Hinojosa V; Tapia JC; Silva-Pavez E; Quezada-Monrás C; Mendoza-Soto P; Salazar-Onfray F; Carrasco C; Niechi I
Cancer Cell Int; 2023 Dec; 23(1):318. PubMed ID: 38072958
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor LKB1 inhibits the progression of gallbladder carcinoma and predicts the prognosis of patients with this malignancy.
Hu MT; Wang JH; Yu Y; Liu C; Li B; Cheng QB; Jiang XQ
Int J Oncol; 2018 Sep; 53(3):1215-1226. PubMed ID: 30015925
[TBL] [Abstract][Full Text] [Related]
20. Galectin-9: An anticancer molecule for gallbladder carcinoma.
Tadokoro T; Morishita A; Fujihara S; Iwama H; Niki T; Fujita K; Akashi E; Mimura S; Oura K; Sakamoto T; Nomura T; Tani J; Miyoshi H; Yoneyama H; Himoto T; Hirashima M; Masaki T
Int J Oncol; 2016 Mar; 48(3):1165-74. PubMed ID: 26797414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
